Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 104 entries
Sorted by: Best Match Show Resources per page
Effectiveness, tolerability and practical application of the newer generation anti-obesity medications.

Drugs in context

MacDaniels JS, Schwartz TL.
PMID: 27114740
Drugs Context. 2016 Mar 08;5:212291. doi: 10.7573/dic.212291. eCollection 2016.

OBJECTIVE: Comparison of the efficacy and tolerability of five newer anti-obesity medications to guide clinical decision making, examining bupropion-naltrexone combination, liraglutide, lorcaserin, orlistat, and phentermine-topiramate combination.METHODS: A brief literature review and internet search for high-powered, randomized and placebo-controlled drug...

Cite
MacDaniels JS, Schwartz TL. Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. Drugs Context. 2016;5:212291doi: 10.7573/dic.212291.
MacDaniels, J. S., & Schwartz, T. L. (2016). Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. Drugs in context, 5212291. https://doi.org/10.7573/dic.212291
MacDaniels, Jeffrey S, and Schwartz, Thomas L. "Effectiveness, tolerability and practical application of the newer generation anti-obesity medications." Drugs in context vol. 5 (2016): 212291. doi: https://doi.org/10.7573/dic.212291
MacDaniels JS, Schwartz TL. Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. Drugs Context. 2016 Mar 08;5:212291. doi: 10.7573/dic.212291. eCollection 2016. PMID: 27114740; PMCID: PMC4831638.
Copy Download .nbib Format: NLM
Intravenous Thrombolysis for a Stroke Mimic Patient.

Case reports in neurology

Nguyen L, Lee JH, Ganti L, Rivera-Morales M, Dub L.
PMID: 34899256
Case Rep Neurol. 2021 Oct 25;13(3):704-709. doi: 10.1159/000519764. eCollection 2021.

The authors present the case of a young woman on phentermine and herbal supplements who presented as an acute stroke alert with right-sided facial droop and numbness. She was treated acutely with intravenous tissue plasminogen activator (tPA). However, the...

Cite
Nguyen L, Lee JH, Ganti L, et al. Intravenous Thrombolysis for a Stroke Mimic Patient. Case Rep Neurol. 2021;13(3):704-709doi: 10.1159/000519764.
Nguyen, L., Lee, J. H., Ganti, L., Rivera-Morales, M., & Dub, L. (2021). Intravenous Thrombolysis for a Stroke Mimic Patient. Case reports in neurology, 13(3), 704-709. https://doi.org/10.1159/000519764
Nguyen, Lilly, et al. "Intravenous Thrombolysis for a Stroke Mimic Patient." Case reports in neurology vol. 13,3 (2021): 704-709. doi: https://doi.org/10.1159/000519764
Nguyen L, Lee JH, Ganti L, Rivera-Morales M, Dub L. Intravenous Thrombolysis for a Stroke Mimic Patient. Case Rep Neurol. 2021 Oct 25;13(3):704-709. doi: 10.1159/000519764. eCollection 2021. PMID: 34899256; PMCID: PMC8613626.
Copy Download .nbib Format: NLM
Adjunctive Use of Appetite Suppressant Medications for Improved Weight Management in Bariatric Surgical Patients.

Obesity surgery

Jester L, Wittgrove AC, Clark W.
PMID: 10729886
Obes Surg. 1996 Oct;6(5):412-415. doi: 10.1381/096089296765556476.

BACKGROUND: Patients who undergo bariatric surgery sometimes experience late onset or weight gain, when they lapse into negative eating patterns, which adversely affect weight management. Long-term weight management is a process, with a surgical foundation, and requiring adjunctive strategies...

Cite
Jester L, Wittgrove AC, Clark W. Adjunctive Use of Appetite Suppressant Medications for Improved Weight Management in Bariatric Surgical Patients. Obes Surg. 1996;6(5):412-415doi: 10.1381/096089296765556476.
Jester, L., Wittgrove, A. C., & Clark, W. (1996). Adjunctive Use of Appetite Suppressant Medications for Improved Weight Management in Bariatric Surgical Patients. Obesity surgery, 6(5), 412-415. https://doi.org/10.1381/096089296765556476
Jester, et al. "Adjunctive Use of Appetite Suppressant Medications for Improved Weight Management in Bariatric Surgical Patients." Obesity surgery vol. 6,5 (1996): 412-415. doi: https://doi.org/10.1381/096089296765556476
Jester L, Wittgrove AC, Clark W. Adjunctive Use of Appetite Suppressant Medications for Improved Weight Management in Bariatric Surgical Patients. Obes Surg. 1996 Oct;6(5):412-415. doi: 10.1381/096089296765556476. PMID: 10729886.
Copy Download .nbib Format: NLM
Retraction and apology: Is phentermine an inhibitor of monoamine oxidase?.

Synapse (New York, N.Y.)

Rothman RB.
PMID: 10400539
Synapse. 1999 Jul;33(1):81; discussion 82. doi: 10.1002/(SICI)1098-2396(199907)33:1<81::AID-SYN8>3.0.CO;2-Z.

No abstract available.

Cite
Rothman RB. Retraction and apology: Is phentermine an inhibitor of monoamine oxidase?. Synapse. 1999;33(1):81; discussion 82doi: 10.1002/(SICI)1098-2396(199907)33:1<81::AID-SYN8>3.0.CO;2-Z.
Rothman, R. B. (1999). Retraction and apology: Is phentermine an inhibitor of monoamine oxidase?. Synapse (New York, N.Y.), 33(1), 81; discussion 82. https://doi.org/10.1002/(SICI)1098-2396(199907)33:1<81::AID-SYN8>3.0.CO;2-Z
Rothman, R B. "Retraction and apology: Is phentermine an inhibitor of monoamine oxidase?." Synapse (New York, N.Y.) vol. 33,1 (1999): 81; discussion 82. doi: https://doi.org/10.1002/(SICI)1098-2396(199907)33:1<81::AID-SYN8>3.0.CO;2-Z
Rothman RB. Retraction and apology: Is phentermine an inhibitor of monoamine oxidase?. Synapse. 1999 Jul;33(1):81; discussion 82. doi: 10.1002/(SICI)1098-2396(199907)33:1<81::AID-SYN8>3.0.CO;2-Z. PMID: 10400539.
Copy Download .nbib Format: NLM
5-alpha-dihydrotestosterone elevations associated with phentermine use.

Therapeutic advances in endocrinology and metabolism

Pearson SM, Trujillo JM, McDermott MT.
PMID: 30181851
Ther Adv Endocrinol Metab. 2018 May 20;9(8):255-258. doi: 10.1177/2042018818776158. eCollection 2018.

BACKGROUND: A case of 5-alpha-dihydrotestosterone (DHT) elevation associated with phentermine initiation is reported, and possible mechanisms are discussed. There are no published reports of this association in the literature.METHODS: Clinical and laboratory information is described.RESULTS: A 72-year-old male with...

Cite
Pearson SM, Trujillo JM, McDermott MT. 5-alpha-dihydrotestosterone elevations associated with phentermine use. Ther Adv Endocrinol Metab. 2018;9(8):255-258doi: 10.1177/2042018818776158.
Pearson, S. M., Trujillo, J. M., & McDermott, M. T. (2018). 5-alpha-dihydrotestosterone elevations associated with phentermine use. Therapeutic advances in endocrinology and metabolism, 9(8), 255-258. https://doi.org/10.1177/2042018818776158
Pearson, Scott M, et al. "5-alpha-dihydrotestosterone elevations associated with phentermine use." Therapeutic advances in endocrinology and metabolism vol. 9,8 (2018): 255-258. doi: https://doi.org/10.1177/2042018818776158
Pearson SM, Trujillo JM, McDermott MT. 5-alpha-dihydrotestosterone elevations associated with phentermine use. Ther Adv Endocrinol Metab. 2018 May 20;9(8):255-258. doi: 10.1177/2042018818776158. eCollection 2018. PMID: 30181851; PMCID: PMC6116762.
Copy Download .nbib Format: NLM
Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis.

The Journal of clinical endocrinology and metabolism

Domecq JP, Prutsky G, Elraiyah T, Wang Z, Mauck KF, Brito JP, Undavalli C, Sundaresh V, Prokop LJ, Montori VM, Murad MH.
PMID: 31365088
J Clin Endocrinol Metab. 2019 Jul 31; doi: 10.1210/jc.2019-01269. Epub 2019 Jul 31.

BACKGROUND: The extent to which some pharmacological interventions reduce or increase the risk of biochemical conversion to T2DM in at-risk individuals is unclear.METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and...

Cite
Domecq JP, Prutsky G, Elraiyah T, et al. Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2019;doi: 10.1210/jc.2019-01269.
Domecq, J. P., Prutsky, G., Elraiyah, T., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., & Murad, M. H. (2019). Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism, . https://doi.org/10.1210/jc.2019-01269
Domecq, Juan Pablo, et al. "Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis." The Journal of clinical endocrinology and metabolism vol. (2019). doi: https://doi.org/10.1210/jc.2019-01269
Domecq JP, Prutsky G, Elraiyah T, Wang Z, Mauck KF, Brito JP, Undavalli C, Sundaresh V, Prokop LJ, Montori VM, Murad MH. Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2019 Jul 31; doi: 10.1210/jc.2019-01269. Epub 2019 Jul 31. PMID: 31365088.
Copy Download .nbib Format: NLM
Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine.

European journal of case reports in internal medicine

Burleigh T, Khandalavala B.
PMID: 32789124
Eur J Case Rep Intern Med. 2020 May 04;7(8):001595. doi: 10.12890/2020_001595. eCollection 2020.

OBJECTIVES: This is the first case report of iatrogenic Takotsubo syndrome (TS) due to a combination of lisdexamfetamine and phentermine.BACKGROUND: TS is characterized by transient acute ballooning of the left ventricular wall. Typically, it occurs in extremely stressed post-menopausal...

Cite
Burleigh T, Khandalavala B. Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine. Eur J Case Rep Intern Med. 2020;7(8):001595doi: 10.12890/2020_001595.
Burleigh, T., & Khandalavala, B. (2020). Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine. European journal of case reports in internal medicine, 7(8), 001595. https://doi.org/10.12890/2020_001595
Burleigh, Tara, and Khandalavala, Birgit. "Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine." European journal of case reports in internal medicine vol. 7,8 (2020): 001595. doi: https://doi.org/10.12890/2020_001595
Burleigh T, Khandalavala B. Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine. Eur J Case Rep Intern Med. 2020 May 04;7(8):001595. doi: 10.12890/2020_001595. eCollection 2020. PMID: 32789124; PMCID: PMC7417048.
Copy Download .nbib Format: NLM
Lorcaserin .

Annals of medicine and surgery (2012)

Elhag W, El Ansari W, Abdulrazzaq S, Elsherif M, Mustafa I.
PMID: 31388419
Ann Med Surg (Lond). 2019 Jul 13;45:75-81. doi: 10.1016/j.amsu.2019.07.024. eCollection 2019 Sep.

BACKGROUND: To evaluate effectiveness, safety, and costs of Lorcaserin METHODS: This retrospective study retrieved charts of all patients (January 2013-June 2016) who received Lorcaserin or phentermine for 3 months. The study assessed anthropometric, glycemic, and lipid changes, as well...

Cite
Elhag W, El Ansari W, Abdulrazzaq S, et al. Lorcaserin . Ann Med Surg (Lond). 2019;45:75-81doi: 10.1016/j.amsu.2019.07.024.
Elhag, W., El Ansari, W., Abdulrazzaq, S., Elsherif, M., & Mustafa, I. (2019). Lorcaserin . Annals of medicine and surgery (2012), 4575-81. https://doi.org/10.1016/j.amsu.2019.07.024
Elhag, Wahiba, et al. "Lorcaserin ." Annals of medicine and surgery (2012) vol. 45 (2019): 75-81. doi: https://doi.org/10.1016/j.amsu.2019.07.024
Elhag W, El Ansari W, Abdulrazzaq S, Elsherif M, Mustafa I. Lorcaserin . Ann Med Surg (Lond). 2019 Jul 13;45:75-81. doi: 10.1016/j.amsu.2019.07.024. eCollection 2019 Sep. PMID: 31388419; PMCID: PMC6677860.
Copy Download .nbib Format: NLM
Off-label drugs for weight management.

Diabetes, metabolic syndrome and obesity : targets and therapy

Hendricks EJ.
PMID: 28652791
Diabetes Metab Syndr Obes. 2017 Jun 10;10:223-234. doi: 10.2147/DMSO.S95299. eCollection 2017.

The global pandemic of obesity and overweight now affects between 2.8 and 3.5 billion of the world population and shows no signs of abatement. Treatment for what is now recognized as a chronic disease includes pharmacotherapy, considered an essential...

Cite
Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223-234doi: 10.2147/DMSO.S95299.
Hendricks, E. J. (2017). Off-label drugs for weight management. Diabetes, metabolic syndrome and obesity : targets and therapy, 10223-234. https://doi.org/10.2147/DMSO.S95299
Hendricks, Ed J. "Off-label drugs for weight management." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 223-234. doi: https://doi.org/10.2147/DMSO.S95299
Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017 Jun 10;10:223-234. doi: 10.2147/DMSO.S95299. eCollection 2017. PMID: 28652791; PMCID: PMC5473499.
Copy Download .nbib Format: NLM
The application of capillary electrophoresis for enantiomeric separation of N,N-dimethylamphetamine and its related analogs: intelligence study on N,N-dimethylamphetamine samples in crystalline and tablet forms.

Forensic science international

Lee WS, Chan MF, Tam WM, Hung MY.
PMID: 16616443
Forensic Sci Int. 2007 Jan 05;165(1):71-7. doi: 10.1016/j.forsciint.2006.03.006. Epub 2006 Apr 17.

This paper reports a new capillary zone electrophoresis method for the simultaneous chiral determination of the enantiomers of N,N-dimethylamphetamine (DMA), methamphetamine (MA), ephedrine (E), pseudoephedrine (PE) and methylephedrine (Me-E). In this study, a number of electophoretic parameters were examined...

Cite
Lee WS, Chan MF, Tam WM, et al. The application of capillary electrophoresis for enantiomeric separation of N,N-dimethylamphetamine and its related analogs: intelligence study on N,N-dimethylamphetamine samples in crystalline and tablet forms. Forensic Sci Int. 2006;165(1):71-7doi: 10.1016/j.forsciint.2006.03.006.
Lee, W. S., Chan, M. F., Tam, W. M., & Hung, M. Y. (2007). The application of capillary electrophoresis for enantiomeric separation of N,N-dimethylamphetamine and its related analogs: intelligence study on N,N-dimethylamphetamine samples in crystalline and tablet forms. Forensic science international, 165(1), 71-7. https://doi.org/10.1016/j.forsciint.2006.03.006
Lee, Wing-Sze, et al. "The application of capillary electrophoresis for enantiomeric separation of N,N-dimethylamphetamine and its related analogs: intelligence study on N,N-dimethylamphetamine samples in crystalline and tablet forms." Forensic science international vol. 165,1 (2007): 71-7. doi: https://doi.org/10.1016/j.forsciint.2006.03.006
Lee WS, Chan MF, Tam WM, Hung MY. The application of capillary electrophoresis for enantiomeric separation of N,N-dimethylamphetamine and its related analogs: intelligence study on N,N-dimethylamphetamine samples in crystalline and tablet forms. Forensic Sci Int. 2007 Jan 05;165(1):71-7. doi: 10.1016/j.forsciint.2006.03.006. Epub 2006 Apr 17. PMID: 16616443.
Copy Download .nbib Format: NLM
Pharmacotherapies for obesity: past, current, and future therapies.

Journal of obesity

Ioannides-Demos LL, Piccenna L, McNeil JJ.
PMID: 21197148
J Obes. 2011;2011:179674. doi: 10.1155/2011/179674. Epub 2010 Dec 12.

Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs...

Cite
Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes. 2010;2011:179674doi: 10.1155/2011/179674.
Ioannides-Demos, L. L., Piccenna, L., & McNeil, J. J. (2011). Pharmacotherapies for obesity: past, current, and future therapies. Journal of obesity, 2011179674. https://doi.org/10.1155/2011/179674
Ioannides-Demos, Lisa L, et al. "Pharmacotherapies for obesity: past, current, and future therapies." Journal of obesity vol. 2011 (2011): 179674. doi: https://doi.org/10.1155/2011/179674
Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes. 2011;2011:179674. doi: 10.1155/2011/179674. Epub 2010 Dec 12. PMID: 21197148; PMCID: PMC3006492.
Copy Download .nbib Format: NLM
Monoamine depletion by reuptake inhibitors.

Drug, healthcare and patient safety

Hinz M, Stein A, Uncini T.
PMID: 22171164
Drug Healthc Patient Saf. 2011;3:69-77. doi: 10.2147/DHPS.S24798. Epub 2011 Oct 20.

BACKGROUND: Disagreement exists regarding the etiology of cessation of the observed clinical results with administration of reuptake inhibitors. Traditionally, when drug effects wane, it is known as tachyphylaxis. With reuptake inhibitors, the placebo effect is significantly greater than the...

Cite
Hinz M, Stein A, Uncini T. Monoamine depletion by reuptake inhibitors. Drug Healthc Patient Saf. 2011;3:69-77doi: 10.2147/DHPS.S24798.
Hinz, M., Stein, A., & Uncini, T. (2011). Monoamine depletion by reuptake inhibitors. Drug, healthcare and patient safety, 369-77. https://doi.org/10.2147/DHPS.S24798
Hinz, Marty, et al. "Monoamine depletion by reuptake inhibitors." Drug, healthcare and patient safety vol. 3 (2011): 69-77. doi: https://doi.org/10.2147/DHPS.S24798
Hinz M, Stein A, Uncini T. Monoamine depletion by reuptake inhibitors. Drug Healthc Patient Saf. 2011;3:69-77. doi: 10.2147/DHPS.S24798. Epub 2011 Oct 20. PMID: 22171164; PMCID: PMC3237392.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 104 entries